Q-omics provides the consensus-scored KIAA1841 profile across patient tissues and cancer cell-line models. KIAA1841 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, KIAA1841 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, KIAA1841 RNA expression shows 20,479 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, BLCA, and UVM as cancer lineages where KIAA1841 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA1841 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA1841 survival associations across molecular data types. KIAA1841 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA1841 RNA expression–survival associations across cancer types. High KIAA1841 expression shows unfavorable associations in MESO, ACC, LIHC, KICH and KIRC, but favorable associations in READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for KIAA1841 RNA expression.
This table summarizes KIAA1841 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KIAA1841. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA1841 shows higher tumor expression in BLCA, KIRP, KIRC, LIHC, UCEC and STAD. The BLCA box plot shows higher KIAA1841 RNA expression in tumor versus normal tissue (log2 FC = +1.605, t-test p < 0.001).
This table shows molecular features associated with KIAA1841 in patient tissues and cancer cell lines. In patient samples, KIAA1841 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA1841 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
